Advertisement
ALNY or INCY or ZTS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Incyte (INCY) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ALNY leads YTD performance at +20.61% with strong 1-year gains of +30.58%, driven by RNAi therapeutics and recent partnerships, but trades at a premium forward P/E of 34.13.
- INCY offers the most attractive valuation with a forward P/E of 11.96 and solid 1-year return of +37.05%, bolstered by oncology approvals like Zynyz in Europe despite recent share pressure.
- ZTS provides stability in animal health with a market cap of $52B, but faces recent weakness including an 8.1% drop over four weeks amid lowered guidance.
- All three stocks show resilience in healthcare, with INCY and ZTS at lower betas (0.84 and 0.95) compared to ALNY's 0.38, balancing growth and risk.
- Relative performance highlights biotech volatility in ALNY versus established revenue streams in INCY and livestock/companion animal demand for ZTS.
- Market sentiment favors value plays amid broader healthcare sector rotation, with INCY showing revenue growth from key drugs like Jakafi.
Introduction
This stock comparison examines ALNY, INCY, and ZTS, three healthcare leaders spanning RNAi therapeutics, oncology, and animal health. Investors seeking exposure to innovative biotech growth, stable pharmaceutical revenues, or defensive animal care sectors will find value in analyzing their relative performance, valuations, and market positioning. Amid recent market volatility, these stocks offer contrasts in momentum, risk profiles, and catalysts, aiding decisions on portfolio allocation for long-term relative performance.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) is a commercial-stage biopharmaceutical firm pioneering RNA interference (RNAi) therapeutics for rare diseases. Its portfolio includes AMVUTTRA and ONPATTRO for ATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with collaborations alongside Novartis and Regeneron. Trading around $316 with a $42B market cap, ALNY has delivered robust YTD gains of +20.61% and +30.58% over one year, within a 52-week range of $206-$496. Recent market activity reflects positive sentiment from partnerships, such as a $1.23B deal with Tenaya Therapeutics for cardiovascular targets and a Helix agreement for precision medicine, offsetting broader biotech pressures. Forward P/E stands at 34.13, signaling growth expectations amid Phase 3 advancements like nucresiran.
INCY Overview and Recent Performance
Incyte Corporation (INCY) focuses on oncology and inflammation, with flagship JAKAFI for myelofibrosis and GVHD, alongside PEMAZYRE, ZYNYZ, and MONJUVI/MINJUVI. The company reported 28% Q4 revenue growth to $1.51B, driven by Jakafi and Opzelura. At approximately $93 and $18.5B market cap, INCY posts YTD +5.84% and 1-year +37.05% returns, in a 52-week span of $54-$112. Recent weeks show mild pressure with a 4.2% drop post-earnings, tempered by European approval for Zynyz in anal cancer and strong cash flows. Valuation appeals with a forward P/E of 11.96 and beta of 0.84, highlighting stability amid pipeline progress in solid tumors.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS) dominates animal health, offering vaccines, parasiticides, and diagnostics for companion animals and livestock. Key segments include dermatology, anti-infectives, and precision tools, marketed globally to veterinarians and producers. Priced near $118 with a $52B market cap—the largest here—ZTS records YTD +5.70% and 1-year +25.67%, against a 52-week range of $114-$172. Recent performance softened with an 8.1% four-week decline due to reduced 2026 outlook and macro trends affecting Librela demand, though fundamentals remain solid with gross margins near 72%. Forward P/E of 16.84 and beta of 0.95 underscore balanced growth in a resilient sector.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and market conditions. Out of 351 total bots, 25 trending ones are highlighted for their adaptability in current volatility, featuring stats like annualized returns up to +208%, win rates of 60-90%, and profit factors exceeding 2.5—such as a minerals-to-aerospace bot at +129.93% annualized with 61.65% win rate. These AI agents employ technical, fundamental, and machine learning analyses for real-time signals in stocks, ETFs, and crypto, suiting swing, scalping, or long-term styles. Explore the page to identify bots aligned with healthcare trends or copy top performers for enhanced relative performance.
Head-to-Head Comparison
ALNY, INCY, and ZTS diverge in business models: ALNY's RNAi innovation targets rare diseases with high growth potential but pipeline dependency, versus INCY's commercial oncology focus yielding steady Jakafi revenues, and ZTS's diversified animal health buffering human pharma risks. Growth drivers include ALNY's partnerships, INCY's label expansions, and ZTS's companion animal demand. Recent momentum favors ALNY YTD, but INCY leads 1-year; ZTS lags short-term. Risk factors: biotech trial volatility for ALNY/ INCY, macro livestock pressures for ZTS. Valuations position INCY cheapest (forward P/E 11.96), ALNY priciest; sentiment tilts toward value amid sector rotation.
Tickeron AI Verdict
Tickeron’s AI currently leans toward INCY for its compelling valuation (forward P/E 11.96), revenue momentum from 28% growth, and European approvals, offering probabilistic upside in oncology relative to peers. ALNY trails due to elevated multiples despite superior YTD trend, while ZTS's stability is weighed by recent guidance cuts. This positioning reflects observable trend consistency and catalysts in the current healthcare environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s), and ZTS’s TA Score reflects 5 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
- ZTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while INCY (@Biotechnology) price change was +1.82% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
INCY is expected to report earnings on Apr 28, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ALNY | INCY | ZTS | |
| Capitalization | 41.3B | 19.5B | 51.5B |
| EBITDA | 631M | 1.76B | 4.07B |
| Gain YTD | -22.127 | -0.962 | -2.319 |
| P/E Ratio | 132.90 | 15.26 | 20.33 |
| Revenue | 3.71B | 5.14B | 9.47B |
| Total Cash | 2.91B | 3.58B | 2.31B |
| Total Debt | 1.28B | 40.4M | 9.24B |
ALNY | INCY | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 78 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 69 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 53 | 72 | 100 | |
SMR RATING 1..100 | 15 | 32 | 16 | |
PRICE GROWTH RATING 1..100 | 62 | 47 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is somewhat better than the same rating for INCY (69) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (94) in the Biotechnology industry. This means that ZTS's stock grew somewhat faster than INCY’s and somewhat faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (53) in the Biotechnology industry is in the same range as INCY (72) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ALNY's stock grew similarly to INCY’s and somewhat faster than ZTS’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is in the same range as INCY (32) in the Biotechnology industry. This means that ALNY's stock grew similarly to ZTS’s and similarly to INCY’s over the last 12 months.
INCY's Price Growth Rating (47) in the Biotechnology industry is in the same range as ZTS (60) in the Pharmaceuticals Generic industry, and is in the same range as ALNY (62) in the Biotechnology industry. This means that INCY's stock grew similarly to ZTS’s and similarly to ALNY’s over the last 12 months.
ZTS's P/E Growth Rating (85) in the Pharmaceuticals Generic industry is in the same range as INCY (100) in the Biotechnology industry, and is in the same range as ALNY (100) in the Biotechnology industry. This means that ZTS's stock grew similarly to INCY’s and similarly to ALNY’s over the last 12 months.
| ALNY | INCY | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 63% | 4 days ago 52% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 57% | 3 days ago 62% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 63% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 67% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 63% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 60% | 3 days ago 54% |
| Advances ODDS (%) | 6 days ago 76% | 11 days ago 61% | 6 days ago 52% |
| Declines ODDS (%) | 3 days ago 66% | 4 days ago 60% | 4 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 67% | 3 days ago 62% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 60% | 3 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IMST | 11.53 | 0.20 | +1.77% |
| Bitwise MSTR Option Income Strategy ETF | |||
| HYDW | 47.02 | 0.15 | +0.32% |
| Xtrackers Low Beta High Yield Bond ETF | |||
| HCRB | 35.40 | 0.09 | +0.25% |
| Hartford Core Bond ETF | |||
| CPSF | 25.97 | 0.06 | +0.25% |
| Calamos S&P 500 Str Alt Prt ETF-Feb | |||
| GOF | 11.29 | 0.01 | +0.09% |
| Guggenheim Strategic Opportunities Fund | |||
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with BMRN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | +2.62% | ||
| BMRN - INCY | 43% Loosely correlated | +1.00% | ||
| PTCT - INCY | 41% Loosely correlated | +1.02% | ||
| GMAB - INCY | 40% Loosely correlated | +0.88% | ||
| TECH - INCY | 39% Loosely correlated | +3.26% | ||
| AXON - INCY | 39% Loosely correlated | +2.49% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 46% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||